KRRO

Business Context and Reporting Period

Korro Bio, Inc. (KRRO) is a clinical-stage biopharmaceutical company focused on developing genetic medicines based on RNA editing using its proprietary OPERA platform. The company completed a reverse merger with Frequency Therapeutics, Inc. in November 2023. This Form 10-K covers the fiscal year ended December 31, 2024. As of the filing date, the company has 104 full-time employees and is headquartered in Cambridge, Massachusetts.

Key Financial Metrics

Note: The filing text does not provide specific gross margin or operating margin percentages as the company has no product sales revenue.

Material Changes vs. Prior Period

• Revenue Recognition: The company recognized $2.3 million in collaboration revenue in 2024 from a new agreement with Novo Nordisk, compared to zero in 2023.
• R&D Expense Increase: R&D expenses increased by $6.4 million (11%) primarily due to a $19.3 million increase in external expenses for the lead candidate KRRO-110 (AATD), driven by manufacturing and clinical trial activities. This was partially offset by a decrease in unallocated pre-development expenses.
• Other Income: Other income, net, increased by $5.1 million to $8.5 million, driven by higher interest income on marketable securities due to interest rates and a larger securities balance.
• Cash Position: Cash and marketable securities decreased by approximately $10 million year-over-year, primarily due to net cash used in operating activities and investing activities (purchases of marketable securities and property/equipment), partially offset by $67.4 million in proceeds from a private placement in April 2024.

Guidance, Outlook, and Risks

Outlook and Milestones:

• KRRO-110 (AATD): The company announced dosing of the first participants in the Phase 1/2a REWRITE clinical trial in January 2025. Interim data is expected in the second half of 2025, with trial completion anticipated in 2026. The FDA granted orphan drug designation in March 2025.
• 3-2-1 Strategy: Management aims to advance three product candidates into clinical trials across two tissue types by the end of 2027.
• Liquidity: Management believes current cash resources ($163.1 million) are sufficient to fund operations into the second half of 2026, including the completion of the REWRITE trial.

Key Risks and Contingencies:

• Profitability: The company has incurred significant losses since inception and expects to continue incurring losses for the foreseeable future. It has never generated revenue from product sales.
• Clinical Uncertainty: RNA editing is a novel technology with limited clinical validation. Preclinical results may not predict clinical success, and the company has dosed very few participants to date.
• Capital Needs: Substantial additional funding will be required. Failure to raise capital could force delays or elimination of R&D programs.
• Intellectual Property: The company relies on patents that may not be granted or may be challenged. Patent terms may expire before commercialization.
• Third-Party Reliance: The company relies on third parties for manufacturing (CMOs) and clinical trial conduct (CROs), introducing supply chain and execution risks.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the "second half of 2026" liquidity estimate against current burn rates and potential delays in the REWRITE trial.
• Novo Nordisk Agreement: Review the specific terms of the $530 million potential collaboration, including the probability of achieving milestones and the recognition of the $2.3 million revenue to date.
• KRRO-110 Clinical Data: Monitor the upcoming interim data release (H2 2025) for safety and pharmacodynamic endpoints, as no clinical efficacy data exists yet.
• Manufacturing Supply Chain: Assess the stability of relationships with Genevant (LNP delivery) and other CMOs, given the reliance on third parties for clinical supply.
• Patent Portfolio: Confirm the status of the 33 patent families and the timeline for expiration (2040-2045) relative to the long development timeline.